- $185.04m
- -$14.80m
- $13.00m
US STOCKS ON THE MOVE-CoreWeave, Moderna, Fox Corp
US STOCKS ON THE MOVE-Cardinal Health, nVent, Acuity
U.S. STOCKS ON THE MOVE-Cardinal Health, Fervo Energy, Rocket Lab
U.S. STOCKS ON THE MOVE-Progress Software, Vicor Corp, Accenture
Evommune gains after eczema drug meets mid-stage trial goal
U.S. STOCKS ON THE MOVE-Apple, Omnicom, Jersey Mike's Subs
U.S. STOCKS ON THE MOVE-Airbnb, Lyft, Korn Ferry
U.S. STOCKS ON THE MOVE-UGI, Chewy, Cognyte Software
U.S. STOCKS ON THE MOVE-Meta, Chime Financial, ServiceTitan
Evommune tumbles after eczema drug fails mid-stage trial goal
Evommune slides; eczema drug misses main goal in trial
Evommune scraps eczema drug after trial miss, shares plunge
U.S. STOCKS ON THE MOVE-Williams-Sonoma, Kraft Heinz, Evommune
Needham starts coverage on Evommune; shares gain
Brief: Evommune Initiates Phase 2B Clinical Trial Of Mrgprx2 Inhibitor Evo756 In Migraine Prophylaxis
U.S. STOCKS ON THE MOVE-Regenxbio, Repay, Natera, Fortune Brands
U.S. STOCKS ON THE MOVE-Regenxbio, Repay, Natera, Fortune Brands
Evommune sinks as skin disease drug fails mid-stage trial
Brief: Evommune Inc - Prospectus Filed For Resale Of Up To 4.5 Million Shares Of Evommune Common Stock By Selling Stockholders - SEC Filing